Cortechs.ai | NeuroQuant®: Contrast agents not required

NeuroQuant®: Contrast agents not required

Factors which degrade the technical quality of MR images or pathologic processes, which significantly affect neuroanatomic structure, may decrease the accuracy of NeuroQuant® output. One of these factors is the use of contrast agents.

Contrast agents are typically used to study vasculature, something that is not needed for volumetric MR imaging. NeuroQuant requires a non-contrasted, 3D T1 sagittal sequence to segment and measure brain structure volumes.

NeuroQuant does not support a contrast enhanced study. The presence of contrast will cause misregistration of cortical and subcortical structures. The segmentation, volumetrics and normative comparisons will be inaccurate when contrast agents are used.

Some examples of NeuroQuant processed with and without contrast agents are shown below.

Cortechs.ai | NeuroQuant®: Contrast agents not required

More information about using NeuroQuant can be found here.

More Resources

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network

07/08/2026

The Hidden Tax on Every Head CT You Read

Why automated, consistent alignment, and the reformats it makes possible, may be the most overlooked upgrade in neuroimaging.

06/23/2026

Helping Our Clients Share Their Success Stories

Learn how Cortechs helps clients share clinical achievements, workflow improvements, and innovation through case studies, testimonials, webinars, and more.

06/15/2026

Alzheimer’s Awareness Month: Bringing Clarity to the Alzheimer’s Care Continuum Through Quantitative Imaging

Explore how quantitative imaging is helping clinicians assess, diagnose, and monitor Alzheimer’s disease and related dementias with greater clarity.

06/08/2026

Cortechs.ai and TAC Center Celebrate One Year of Advancing Neuroimaging Innovation in Peru

TAC Centers Peru is celebrating one year of integrating the NeuroQuant® suite into clinical practice.

06/04/2026

SNMMI 2026: Advancing the Future of Quantitative PET in Dementia Imaging

At SNMMI 2026, Cortechs.ai showcased NeuroQuant® PET and the growing role of quantitative PET imaging in dementia care.
Scroll to Top